Professor Ed Lavelle
Prof/ Course Co-Ordinator, Biochemistry
Biography
I am an Immunologist and was Head of the School of Biochemistry and Immunology from 2017-2020. I have engaged at teaching at many levels in Universities in Ireland and the U.K. In particular, since October 2004 I have worked as a lecturer, senior lecturer and Professor in Immunology in the School of Biochemistry and Immunology at Trinity College Dublin. In addition to delivering lectures and tutorials to junior and senior sophister students, I have also lectured to students enrolled on the MSc courses in Molecular Medicine, Immunology and Translational Oncology. I was also previously engaged in lecturing at TCD and at the University of Nottingham (England).
I have supervised student projects from diploma to Masters degree level and have supervised 21 PhD students to completion. I have was President of the Irish Society for Immunology from 2012-2020, organised a number of National and International conferences, chaired sessions on Immunology and vaccines for a number of national and international conferences and acted as a peer reviewer for leading Immunology journals and for funding bodies in both the EU and the USA. Since acquiring my PhD in 1994, my research has been principally in the fields of Immunology and vaccine adjuvant development. The projects I have worked on have included the piscine mucosal immune system, the use of biodegradable micro and nanoparticles as vaccine adjuvants and the evaluation of plant lectins as bioadhesives, immunogens and immunomodulators. During this time I acquired broad expertise that is applicable to the range of projects I am now engaged in and will pursue in the future.
In recent years my principal research interest has been the elucidation of the mechanism of action of adjuvants and immunomodulators. In particular I have focused on on particulate vaccine adjuvants including biodegradable microparticles, alum and the cationic polysaccharide chitosan. This work includes basic research into the mechanism by which these systems activate the immune system and more applied work on the optimisation of these adjuvants for use in injectable and mucosal vaccines. The fundamental adjuvant research includes studies into the cell signalling pathways induced by these molecules which will facilitate a better understanding of their mode(s) of action. In addition, over the past number of years my team have worked closely with our collaborators within AMBER to address the potential of novel biomaterials to drive beneficial immune responses underpinning tissue regeneration. Across all of our activities we depend on building and sustaining close collaborations with national and international academic and industrial collaborators.
Publications and Further Research Outputs
Peer-Reviewed Publications
Lavelle, E.C. and Genescà , M., Editorial overview: The march of mucosal vaccines, Current Opinion in Immunology, 86, (102408), 2024
Ed C. Lavelle, Craig P. McEntee, Vaccine adjuvants: Tailoring innate recognition to send the right message, Immunity, 57, (4), 2024, p772-789
Jorge Huete"Carrasco, Roisin I. Lynch, Ross W. Ward, Ed C. Lavelle, Rational design of polymer"based particulate vaccine adjuvants, European Journal of Immunology, 54, (2), 2024
Joanna L. Turley, Ross W. Ward, Jorge Huete-Carrasco, Natalia Muñoz-Wolf, Kate Roche, Lei Jin, Andrew Bowie, Mats Andersson, Ed Lavelle, Intratumoral delivery of the chitin-derived C100 adjuvant promotes robust STING, IFNAR, and CD8+ T cell-dependent anti-tumor immunity, Cell Reports Medicine, 5, (5), 2024, p101560
Muñoz-Wolf, N. and Ward, R.W. and Hearnden, C.H. and Sharp, F.A. and Geoghegan, J. and O'Grady, K. and McEntee, C.P. and Shanahan, K.A. and Guy, C. and Bowie, A.G. and Campbell, M. and Roces, C.B. and Anderluzzi, G. and Webb, C. and Perrie, Y. and Creagh, E. and Lavelle, E.C., Non-canonical inflammasome activation mediates the adjuvanticity of nanoparticles, Cell Reports Medicine, 4, (1), 2023
Huete-Carrasco J, Lavelle EC., Immunostimulatory nanoparticles go viral., Nature materials, 22, (3), 2023, p273-275
Oleszycka E, O'Brien EC, Freeley M, Lavelle EC, Long A., Bile acids induce IL-1" and drive NLRP3 inflammasome-independent production of IL-1ß in murine dendritic cells., Frontiers in immunology, 14, 2023, p1285357
Sullivan, G.P. and Davidovich, P. and Muñoz-Wolf, N. and Ward, R.W. and Hernandez Santana, Y.E. and Clancy, D.M. and Gorman, A. and Najda, Z. and Turk, B. and Walsh, P.T. and Lavelle, E.C. and Martin, S.J., Myeloid cell-derived proteases produce a proinflammatory form of IL-37 that signals via IL-36 receptor engagement, Science immunology, 7, (78), 2022, peade5728
Turley, J.L. and Lavelle, E.C., Resolving adjuvant mode of action to enhance vaccine efficacy, Current Opinion in Immunology, 77, (102229), 2022
Lynch RI, Lavelle EC., Immuno-modulatory biomaterials as anti-inflammatory therapeutics., Biochemical pharmacology, 197, 2022, p114890
Muñoz-Wolf N, Lavelle EC., Promotion of trained innate immunity by nanoparticles., Seminars in immunology, 2021, p101542
Albutti, A. and Longet, S. and McEntee, C.P. and Quinn, S. and Liddicoat, A. and Rîmniceanu, C. and Lycke, N. and Lynch, L. and Cardell, S. and Lavelle, E.C., Type ii nkt cell agonist, sulfatide, is an effective adjuvant for oral heat-killed cholera vaccines, Vaccines, 9, (6), 2021
Dowling JK, Afzal R, Gearing LJ, Cervantes-Silva MP, Annett S, Davis GM, De Santi C, Assmann N, Dettmer K, Gough DJ, Bantug GR, Hamid FI, Nally FK, Duffy CP, Gorman AL, Liddicoat AM, Lavelle EC, Hess C, Oefner PJ, Finlay DK, Davey GP, Robson T, Curtis AM, Hertzog PJ, Williams BRG, McCoy CE , Mitochondrial arginase-2 is essential for IL-10 metabolic reprogramming of inflammatory macrophages, Nature Communications, 12, (1), 2021, p1460-
Scott, L.M. and Vincent, E.E. and Hudson, N. and Neal, C. and Jones, N. and Lavelle, E.C. and Campbell, M. and Halestrap, A.P. and Dick, A.D. and Theodoropoulou, S., Interleukin-33 regulates metabolic reprogramming of the retinal pigment epithelium in response to immune stressors, JCI Insight, 6, (8), 2021
Lavelle, E.C. and Ward, R.W., Mucosal vaccines â" fortifying the frontiers, Nature Reviews Immunology, 2021
Turley JL, Lavelle EC., Fatballs foster fabulous follicles., Immunity, 54, (12), 2021, p2695-2697
Turley, J.L. and Moran, H.B.T. and McEntee, C.P. and O'Grady, K. and Muñoz-Wolf, N. and Jin, L. and Follmann, F. and Andersen, P. and Andersson, M. and Lavelle, E.C., Chitin-derived polymer deacetylation regulates mitochondrial reactive oxygen species dependent cGAS-STING and NLRP3 inflammasome activation, Biomaterials, 275, (120961), 2021
Lavelle, E.C. and Ward, R.W., Publisher Correction: Mucosal vaccines â" fortifying the frontiers (Nature Reviews Immunology, (2021), 10.1038/s41577-021-00583-2), Nature Reviews Immunology, 2021
Z. Zas³ona , E. Flis, M.M. Wilk, R.G. Carroll, E.M. Palsson-McDermott, M.M. Hughes, C. Diskin, K. Banahan, D.G. Ryan, A. Hooftman, A. Misiak, J. Kearney, G. Lochnit, W. Bertrams, T. Greulich, B. Schmeck, O.J. McElvaney, K.H.G. Mills, E.C. Lavelle, M. Wygrecka, E.M. Creagh & L.A.J. O'Neill , Caspase-11 promotes allergic airway inflammation, Nature Communications, 2020
Schijns, V., Fernández-Tejada, A., Barjaktarović, Z., Bouzalas, I., Brimnes, J., Chernysh, S., Gizurarson, S., Gursel, I., Jakopin, Z., Lawrenz, M., Nativi, C., Paul, S., Pedersen, G.K., Rosano, C., Ruiz-de-Angulo, A., Slütter, B., Thakur, A., Christensen, D. and Lavelle, E.C., Modulation of immune responses using adjuvants to facilitate therapeutic vaccination. , Immunological Reviews , 2020
Craig P. McEntee, Hannah B.T. Moran, Natalia Muñoz-Wolf, Alex M. Liddicoat, Elizabeth C. Carroll, Jeanette Erbo-Wern, Ivan S. Coulter, Peter Andersen, Frank Follmann, Ed C. Lavelle, Type I IFN signalling is required for cationic adjuvant formulation (CAF)01-induced cellular immunity and mucosal priming, Vaccine, 38, (3), 2020, p635--643
Shears RK, Jacques LC, Naylor G, Miyashita L, Khandaker S, Lebre F, Lavelle EC, Grigg J, French N, Neill DR, Kadioglu A., Exposure to diesel exhaust particles increases susceptibility to invasive pneumococcal disease., The Journal of allergy and clinical immunology, 145, (4), 2020, p1272-1284.e6
Lavelle, E.C. and Carsetti, R. and Pickl, W.F. and Wiedermann, U., Editorial: Challenges in Vaccinology, Frontiers in Immunology, 11, (632537), 2020
Lemoine C, Thakur A, Kraji"nik D, Guyon R, Longet S, Razim A, Górska S, Panteli" I, Ili" T, Nikoli" I, Lavelle EC, Gamian A, Savi" S, Milicic A., Technological Approaches for Improving Vaccination Compliance and Coverage., Vaccines, 8, (2), 2020, pE304-
Lundahl, M. and Lynch, D.M. and Barnes, D. and McSweeney, L. and Gorman, A. and Lebre, F. and Gordon, S.V. and Lavelle, E.C. and Scanlan, E.M., Mycobacterial para-Hydroxybenzoic Acid-Derivatives (pHBADs) and Related Structures Induce Macrophage Innate Memory, ACS Chemical Biology, 15, (9), 2020, p2415-2421
McEntee, C.P., Moran, H.B.T., Muñoz-Wolf, N., Liddicoat, A.M., Carroll, E.C., Erbo-Wern, J., Coulter, I.S., Andersen, P., Follmann, F. and Lavelle, E.C. (2020). , Type I IFN signalling is required for cationic adjuvant formulation (CAF)01-induced cellular immunity and mucosal priming. , Vaccine, 38, (3), 2020, p635 - 643
Lebre F, Boland JB, Gouveia P, Gorman AL, Lundahl MLE, I Lynch R, O'Brien FJ, Coleman J, Lavelle EC., Pristine graphene induces innate immune training., Nanoscale, 12, (20), 2020, p11192-11200
Hackett, E.E., Charles-Messance, H., O'Leary, S.M., Gleeson, L.E., Muñoz-Wolf, N., Case, S., Wedderburn, A., Johnston, D.G.W., Williams, M.A., Smyth, A., Ouimet, M., Moore, K.J., Lavelle, E.C., Corr, S.C., Gordon, S.V., Keane, J., Sheedy, F.J., Mycobacterium tuberculosis Limits Host Glycolysis and IL-1ß by Restriction of PFK-M via MicroRNA-21, Cell Reports, 30, (1), 2020, p124-136.e4
Schijns V, Lavelle EC., Prevention and treatment of COVID-19 disease by controlled modulation of innate immunity., European journal of immunology, 2020
Mimmi Lundahl, Dylan M. Lynch, Danielle Barnes, Lauren McSweeney, Aoife Gorman, Filipa Lebre, Stephen V. Gordon, Ed C. Lavelle, Eoin M. Scanlan, Mycobacterial para-Hydroxybenzoic Acid-Derivatives (pHBADs) and Related Structures Induce Macrophage Innate Memory, ACS Chemical Biology, 2020
Shears, R.K., Jacques, L.C., Naylor, G., Miyashita, L., Khandaker, S., Lebre, F. and Lavelle, E.C., Grigg, J., French, N., Neill, D.R. and Kadioglu, A. , Exposure to diesel exhaust particles increases susceptibility to invasive pneumococcal disease. , J Allergy Clin Immunol., 145, (4), 2020, p1272 - 1284
Emma B. O'Connor, Natalia Muñoz-Wolf, Gemma Leon, Ed C. Lavelle, Kingston H. G. Mills, Patrick T. Walsh and Richard K. Porter, UCP3 reciprocally controls CD4+ Th17 and Treg cell differentiation, PLoS ONE, 15, (11), 2020, pe02-
Lebre, F. and Lavelle, E.C. and Borges, O., Easy and effective method to generate endotoxin-free chitosan particles for immunotoxicology and immunopharmacology studies, Journal of Pharmacy and Pharmacology, 71, (6), 2019, p920-928
Davitt, C.J.H. and Longet, S. and Albutti, A. and Aversa, V. and Nordqvist, S. and Hackett, B. and McEntee, C.P. and Rosa, M. and Coulter, I.S. and Lebens, M. and Tobias, J. and Holmgren, J. and Lavelle, E.C., Alpha-galactosylceramide enhances mucosal immunity to oral whole-cell cholera vaccines, Mucosal Immunology, 12, (4), 2019, p1055-1064
Sinéad Kenealy∗, Joan Manils∗, Mathilde Raverdeau Natalia Munoz-Wolf, Gillian Barber, Alex Liddicoat, Ed C.Lavelle Emma M.Creagh , Caspase-11 Mediated Cell Death Contributes to the Pathogenesis of Imiquimod-Induced Psoriasis, Journal of Investigative Dermatology, 2019, p2389 - 2393
Jiménez, J.M. and Salazar, M.L. and Arancibia, S. and Villar, J. and Salazar, F. and Brown, G.D. and Lavelle, E.C. and MartÃnez-Pomares, L. and Ortiz-Quintero, J. and Lavandero, S. and Manubens, A. and Becker, M.I., TLR4, but neither dectin-1 nor dectin-2, participates in the mollusk hemocyanin-induced proinflammatory effects in antigen-presenting cells from mammals, Frontiers in Immunology, 10, (MAY), 2019
Carty, M. and Kearney, J. and Shanahan, K.A. and Hams, E. and Sugisawa, R. and Connolly, D. and Doran, C.G. and Muñoz-Wolf, N. and GÃ"rtler, C. and Fitzgerald, K.A. and Lavelle, E.C. and Fallon, P.G. and Bowie, A.G., Cell Survival and Cytokine Release after Inflammasome Activation Is Regulated by the Toll-IL-1R Protein SARM, Immunity, 50, (6), 2019, p1412-1424.e6
McEntee, C.P. and Finlay, C.M. and Lavelle, E.C., Divergent roles for the IL-1 family in gastrointestinal homeostasis and inflammation, Frontiers in Immunology, 10, (JUN), 2019
O'Grady, K., Hearnden, C.C.H., Bento, D., Oleszycka, E., Andersen, P., Muñoz-Wolf, N. and Lavelle, E.C. , IL-33 is a negative regulator of vaccine-induced antigen-specific cellular immunity, The Journal of Immunology, 2019
Liddicoat, A.M. and Lavelle, E.C., Modulation of innate immunity by cyclosporine A, Biochemical Pharmacology, 163, 2019, p472-480
Alex M. Liddicoat, Ed C. Lavelle, Modulation of innate immunity by cyclosporine A, Biochemical Pharmacology, 2019
Longet, S. and Abautret-Daly, A. and Davitt, C.J.H. and McEntee, C.P. and Aversa, V. and Rosa, M. and Coulter, I.S. and Holmgren, J. and Raghavan, S. and Lavelle, E.C., An oral alpha-galactosylceramide adjuvanted Helicobacter pylori vaccine induces protective IL-1R- and IL-17R-dependent Th1 responses, npj Vaccines, 4, (1), 2019
Nazmi, A., Field, R.H., Griffin, E.W., Haugh, O., Hennessy, E., Cox, D., Reis, R., Tortorelli, L., Murray, C.L., Lopez-Rodriguez, A.B., Lavelle, E.C., Dunne, A. and Cunningham,C. , Chronic neurodegeneration induces Type I interferon synthesis via STING, shaping microglial phenotype and accelerating disease progression, Glia, 67, 2019, p1254 - 1276
Munoz-Wolf, N. and Lavelle, E.C., A Guide to IL-1 family cytokines in adjuvanticity, FEBS Journal, 285, (13), 2018, p2377 - 2401
Clancy, D.M. and Sullivan, G.P. and Moran, H.B.T. and Henry, C.M. and Reeves, E.P. and McElvaney, N.G. and Lavelle, E.C. and Martin, S.J., Extracellular Neutrophil Proteases Are Efficient Regulators of IL-1, IL-33, and IL-36 Cytokine Activity but Poor Effectors of Microbial Killing, Cell Reports, 22, (11), 2018, p2809-2817
Filipa Lebre, Damien Hanlon, John B. Boland, Jonathan Coleman, Ed C. Lavelle, Exfoliation in Endotoxin"Free Albumin Generates Pristine Graphene with Reduced Inflammatory Properties, Advanced Biosystems, 2018, p1800102
Lebre, F., Hanlon, D., Boland, J.B., Coleman, J. and Lavelle E.C. , Exfoliation in Endotoxin‐Free Albumin Generates Pristine Graphene with Reduced Inflammatory Properties., Advanced Biosystems, 2, (12), 2018, p1800102-
Lavelle, E.C. and McLachlan, J.B., Editorial overview: Immunomodulation: Striking the right balance: using immunomodulators to target infectious diseases, cancer, and autoimmunity, Current Opinion in Pharmacology, 41, 2018, pvii-ix
Moran, H.B.T., Turley, J., Andersen, M. and Lavelle, E.C , Immunomodulatory properties of chitosan polymers. , Biomaterials, 184, 2018, p1 - 9
Longet S, Lundahl MLE, Lavelle EC., Targeted Strategies for Mucosal Vaccination., Bioconjugate Chemistry, 29, (3), 2018, p613 - 623
Lebre, F., Pedroso de Lima, M.C., Lavelle, E.C. and Borges, O , Mechanistic study of the adjuvant effect of chitosan-aluminum nanoparticles., International Journal of Pharmaceutics, 552, (112), 2018, p12 - 15
Oleszycka, E., McCluskey, S., Sharp, F.A., Muñoz-Wolf, N., Hams, E., Gorman, A.L., Fallon, P.G. and Lavelle EC., The vaccine adjuvant alum promotes IL-10 production that suppresses Th1 responses., European Journal of Immunology, 2018, 705-715
F. Lebre, M.C. Pedroso de Lima, Ed C. Lavelle, O. Borges, Mechanistic study of the adjuvant effect of chitosan-aluminum nanoparticles, International Journal of Pharmaceutics, 2018
Lavelle, E.C. and McLachlan,J., Striking the right balance: using immunomodulators to target infectious diseases, cancer and autoimmunity, Current Opinion in Pharmacology, 41, 2018, pvii - ix
Barnes, D.D. and Lundahl, M.L.E. and Lavelle, E.C. and Scanlan, E.M., The Emergence of Phenolic Glycans as Virulence Factors in Mycobacterium tuberculosis, ACS Chemical Biology, 12, (8), 2017, p1969-1979
Lundahl, M.L.E. and Scanlan, E.M. and Lavelle, E.C., Therapeutic potential of carbohydrates as regulators of macrophage activation, Biochemical Pharmacology, 146, 2017, p23-41
Tivnan, A., Heilinger, T., Lavelle, E.C. and Prehn, J.H.M. , Advances in immunotherapy for the treatment of glioblastoma., Journal of Neuro-Oncology, 131, (1), 2017, p1-9
Moore C., Movia D., Smith R., Hanlon D., Lebre F., Lavelle E., Byrne H., Coleman J., Volkov Y., McIntyre J., Industrial grade 2D molybdenum disulphide (MoS2): an in vitro exploration of the impact on cellular uptake, cytotoxicity, and inflammation, 2D Materials, 4, (2), 2017
Longet, S., Aversa, V., O'Donnell, D., Tobias, J., Rosa, M., Holmgren, J., Coulter, I.S. and Lavelle, E.C., Thermostability of the coating, antigen and immunostimulator in an adjuvanted oral capsule vaccine formulation, International Journal of Pharmaceutics, 534, (1-2), 2017, p60-70
Munoz-Wolf, N. and Lavelle, E.C., Hippo interferes with antiviral defences, Nature Cell Biology, 19, (4), 2017, p267-269
Harte, C., Gorman, A.L., McCluskey, S., Carty, M., Bowie, A.G., Scott, C.J., Meade, K.G. and Lavelle, E.C., Alum activates the bovine NLRP3 inflammasome, Frontiers in Immunology, 8, 2017, p1494-
Lebre, F., Sridharan, R., Sawkins, M.J., Kelly, D.J., O'Brien, F.J. and Lavelle, E.C., The shape and size of hydroxyapatite particles dictate inflammatory responses following implantation, Scientific Reports, 7, (1), 2017, p2922 -
Ní Cheallaigh, C., Sheedy, F.J., Harris, J., Muñoz-Wolf, N., Lee, J., West, K., McDermott, E.P., Smyth, A., Gleeson, L.E., Coleman, M., Martinez, N., Hearnden, C.H., Tynan, G.A., Carroll, E.C., Jones, S.A., Corr, S.C., Bernard, N.J., Hughes, M.M., Corcoran, S.E., O'Sullivan, M., Fallon, C.M., Kornfeld, H., Golenbock, D., Gordon, S.V., O'Neill, L.A., Keane, J. Lavelle, E.C, A Common Variant in the Adaptor Mal Regulates Interferon Gamma Signaling., Immunity, 44, (2), 2016, p368 - 379
Muñoz-Wolf N, Lavelle EC., Innate Immune Receptors., Methods Mol Biol., 1417, 2016, p1 - 43
Pandiyan P, Lavelle E.C, Editorial: Immune cells in the mucosa, Frontiers in Immunology, 7, (DEC), 2016, p00657-
Lebre, F., Hearnden, C.H., Lavelle, E.C., Modulation of Immune Responses by Particulate Materials, Advanced Materials, 2016, 5525-5541
Innate immune receptors in, editor(s)Pablo Pelegrin and Francesco Di Virgilio , Nod Like Receptors, Springer, 2016, pp1-43 , [Muñoz-Wolf, N and Lavelle, E.C. ]
Carroll, E.C., Jin, L., Mori, A., Muñoz-Wolf, N., Oleszycka, E., Moran, H.B.T., Mansouri, S., McEntee, C.P., Lambe, E., Agger, E.M., Andersen, P., Cunningham, C., Hertzog, P., Fitzgerald, K.A., Bowie, A.G., Lavelle, E.C., The Vaccine Adjuvant Chitosan Promotes Cellular Immunity via DNA Sensor cGAS-STING-Dependent Induction of Type I Interferons, Immunity, 44, (3), 2016, p597 - 608
Hughes, C.S., Colhoun, L.M., Bains, B.K., Kilgour, J.D., Burden, R.E., Burrows, J.F., Lavelle, E.C., Gilmore, B.F., Scott, C.J., Extracellular cathepsin S and intracellular caspase 1 activation are surrogate biomarkers of particulate-induced lysosomal disruption in macrophages, Particle and Fibre Toxicology, 13, (1), 2016, p19-
Lavelle, E.C. and Tomar, J., Mucosal vaccines, adjuvants and delivery 2016 - A meetings management conference, Drugs of the Future, 41, (11), 2016, p689-695
Oleszycka, E., Moran, H.B.T., Tynan, G.A., Hearnden, C.H., Coutts, G., Campbell, M., Allan, S.M., Scott, C.J. and Lavelle, E.C. , IL-1α and inflammasome-independent IL-1β promote neutrophil infiltration following alum vaccination. , FEBS Journal, 283, (1), 2016, p9 - 24
The Role of Inflammasomes in Adjuvant-Driven Humoral and Cellular Immune Responses in, editor(s)Virgil Schijns and Derek O'Hagan , Immunopotentiators in Modern Vaccines , 2016, pp23-42 , [Munoz-Wolf, N., McCluskey, S. and Lavelle, E.C.]
Finlay CM, Stefanska AM, Walsh KP, Kelly PJ, Boon L, Lavelle EC, Walsh PT, Mills KH., Helminth Products Protect against Autoimmunity via Innate Type 2 Cytokines IL-5 and IL-33, Which Promote Eosinophilia., Journal of Immunology, 196, (2), 2016, p703-714
Davitt, C.J.H., McNeela, E.A., Longet, S., Tobias, J., Aversa, V., McEntee, C.P., Rosa, M., Coulter, I.S., Holmgren, J., Lavelle, E.C., A novel adjuvanted capsule based strategy for oral vaccination against infectious diarrhoeal pathogens, Journal of Controlled Release, 233, 2016, p162-173
Schwartz, C., O'Grady, K., Lavelle, E.C., Fallon, P.G., Interleukin 33: An innate alarm for adaptive responses beyond Th2 immunity-emerging roles in obesity, intestinal inflammation, and cancer, European Journal of Immunology, 46, (5), 2016, p1091-1100
Antigen Delivery Systems I: Nonliving Microparticles, Liposomes, and Immune-Stimulating Complexes (ISCOMs) in, Mucosal Immunology, 2015, pp1211-1231 , [McEntee, C., Lavelle, E.C., O'Hagan, D.T.]
Davitt, C.J.H., Lavelle, E.C., Delivery strategies to enhance oral vaccination against enteric infections, Advanced Drug Delivery Reviews, 2015
Kearney CJ, Cullen SP, Tynan GA, Henry CM, Clancy D, Lavelle EC, Martin SJ, Necroptosis suppresses inflammation via termination of TNF- or LPS-induced cytokine and chemokine production., Cell death and differentiation, 22, 2015, p1313-1327
Brown AF, Murphy AG, Lalor SJ, Leech JM, O'Keeffe KM, Mac Aogáin M, O'Halloran DP, Lacey KA, Tavakol M, Hearnden CH, Fitzgerald-Hughes D, Humphreys H, Fennell JP, van Wamel WJ, Foster TJ, Geoghegan JA, Lavelle EC, Rogers TR, McLoughlin RM, Memory Th1 Cells Are Protective in Invasive Staphylococcus aureus Infection., PLoS pathogens, 11, (11), 2015, pe1005226
Tynan, GA, Hearnden, CH, Oleszycka, E, Lyons, CL, Coutts, G, O'Connell, J, Corrigan, MA, Lynch, L, Campbell, M, Callanan, JJ, Mok, KH, Geoghegan, J, O'Farrelly, C, Allan, SM, Roche, HM, O'Shea, DB, Lavelle, EC, Endogenous Oils Derived From Human Adipocytes Are Potent Adjuvants That Promote IL-1 alpha-Dependent Inflammation, Diabetes, 63, (6), 2014, p2037-2050
Oleszycka, E., Lavelle, E.C., Immunomodulatory properties of the vaccine adjuvant alum, Current Opinion in Immunology, 28, (1), 2014, p1-5
Tynan GA, Hearnden CH, Oleszycka E, Lyons CL, Coutts G, O'Connell J, Corrigan MA, Lynch L, Campbell M, Callanan JJ, Mok KH, Geoghegan J, O'Farrelly C, Allan SM, Roche HM, O'Shea DB, Lavelle EC, Endogenous oils derived from human adipocytes are potent adjuvants that promote IL-1 alpha-dependent inflammation., Diabetes, 63, (3), 2014, p2037-2050
Abautret-Daly AE, Davitt CJ, Lavelle EC, Harnessing the antibacterial and immunological properties of mucosal-associated invariant T cells in the development of novel oral vaccines against enteric infections., Biochemical pharmacology, 92, (2), 2014, p173-83
Bourke J, Brereton CF, Gordon SV, Lavelle EC and Scanlan EM, The Synthesis and Biological Evaluation of Mycobacterial p-Hydroxybenzoic Acid Derivatives (p-HBADs), Organic & Biomolecular Chemistry, 12, (7), 2014, p1114-1123
Bourke, J., Brereton, C.F., Gordon, S.V., Lavelle, E.C., Scanlan, E.M., The synthesis and biological evaluation of mycobacterial p-hydroxybenzoic acid derivatives (p-HBADs), Organic and Biomolecular Chemistry, 12, (7), 2014, p1114-1123
Doyle SL, Ozaki E, Brennan K, Humphries MM, Mulfaul K, Keaney J, Kenna PF, Maminishkis A, Kiang AS, Saunders SP, Hams E, Lavelle EC, Gardiner C, Fallon PG, Adamson P, Humphries P, Campbell M, IL-18 attenuates experimental choroidal neovascularization as a potential therapy for wet age-related macular degeneration., Science translational medicine, 6, (230), 2014, p230ra44
Doyle, SL, Ozaki, E, Brennan, K, Humphries, MM, Mulfaul, K, Keaney, J, Kenna, PF, Maminishkis, A, Kiang, AS, Saunders, SP, Hams, E, Lavelle, EC, Gardiner, C, Fallon, PG, Adamson, P, Humphries, P, Campbell, M, IL-18 Attenuates Experimental Choroidal Neovascularization as a Potential Therapy for Wet Age-Related Macular Degeneration, SCIENCE TRANSLATIONAL MEDICINE, 6, 2014, p230-
Oleszycka, E. and Lavelle, E.C, The immunomodulatory properties of the vaccine adjuvant alum., Current Opinion in Immunology, 28C, 2014, p1 - 5
Ismail M. Meraza, Claire H.A Hearnden, Xuewu Liua, Marie Yang, Laura Williams, Jianhua Gua, Jessica R. Rhudy, Kenji Yokoi, Ed C. Lavelle and Rita E. Serda , Multivalent presentation of MPL by porous silicon microparticles favors T helper 1 polarization increasing the anti-tumor efficacy of doxorubicin nanoliposomes, PLoS One, 2014, p0094703-
Misstear K, McNeela EA, Murphy AG, Geoghegan JA, O'Keeffe KM, Fox J, Chan K, Heuking S, Collin N, Foster TJ, McLoughlin RM, Lavelle EC, Targeted nasal vaccination provides antibody independent protection against Staphylococcus aureus., The Journal of infectious diseases, 209, (9), 2014, p1479-1484
Arancibia, S., Espinoza, C., Salazar, F., Del Campo, M., Tampe, R., Zhong, T-Y., De Ioannes, P., Moltedo, B., Ferreira, J., Lavelle, E.C., Manubens, A., De Ioannes, A.E. and Becker, M.I., A novel immunomodulatory hemocyanin from the limpet Fissurella latimarginata exhibits outstanding anti-tumor activity in melanoma., PLoS One, 9, (1), 2014, pe87240
Arancibia, S., Espinoza, C., Salazar, F., Del Campo, M., Tampe, R., Zhong, T.-Y., De Ioannes, P., Moltedo, B., Ferreira, J., Lavelle, E.C., Manubens, A., De Ioannes, A.E., Becker, M.I., A novel immunomodulatory hemocyanin from the limpet Fissurella latimarginata promotes potent anti-tumor activity in melanoma, PLoS ONE, 9, (1), 2014, pe94703-
Yang, M., Hearnden, C.H.A., Oleszycka, E., Lavelle, E.C., NLRP3 inflammasome activation and cytotoxicity induced by particulate adjuvants, Methods in Molecular Biology, 1040, 2013, p41-63
Cullen SP, Henry CM, Kearney CJ, Logue SE, Feoktistova M, Tynan GA, Lavelle EC, Leverkus M, Martin SJ, Fas/CD95-Induced Chemokines Can Serve as "Find-Me" Signals for Apoptotic Cells., Molecular cell, 49, 2013, p1-15
Adjuvant Strategies in Vaccines. in, editor(s)Prendergast/Jaffee , Cancer Immunotherapy: Immune Suppression and Tumor Growth, Academic Press, 2013, pp333-349 , [Hearnden, C and Lavelle, E.C.]
Yang, M., Flavin, K., Kopf, I., Radics, G., Hearnden, C.H.A., McManus, G.J., Moran, B., Villalta-Cerdas, A., Echegoyen, L.A., Giordani, S. and Lavelle, E.C. , Chemical surface functionalization of carbon nanoparticles modulates inflammatory cell recruitment and NLRP3 inflammasome activation, Small, 9, (24), 2013, p4194 - 4206
Ross PJ, Sutton CE, Higgins S, Allen AC, Walsh K, Misiak A, Lavelle EC, McLoughlin RM, Mills KH, Relative Contribution of Th1 and Th17 Cells in Adaptive Immunity to Bordetella pertussis: Towards the Rational Design of an Improved Acellular Pertussis Vaccine., PLoS pathogens, 9, (4), 2013, pe1003264
Ruane, DT., Brane, L., Reis, B., Cheong, C., Poles, J., Do, Y., Zhu, H., Velinzon, K., Choi, J-H., Studt, N., Mayer, L., Lavelle, E.C., Steinman, R., Mucida, D and Mehandru, S. , Lung dendritic cells induce migration of protective T cells to the gastrointestinal tract., The Journal of Experimental Medicine, 210, (9), 2013, p1871-1888
Kearney CJ, Sheridan C, Cullen SP, Tynan GA, Logue SE, Afonina IS, Vucic D, Lavelle EC, Martin SJ, Inhibitor of Apoptosis Proteins (IAPs) and Their Antagonists Regulate Spontaneous and Tumor Necrosis Factor (TNF)-induced Proinflammatory Cytokine and Chemokine Production., The Journal of biological chemistry, 288, (7), 2013, p4878-4890
Maher BM, Mulcahy ME, Murphy AG, Wilk M, O'Keeffe KM, Geoghegan JA, Lavelle EC, McLoughlin RM, Nlrp-3-driven interleukin 17 production by γδT cells controls infection outcomes during Staphylococcus aureus surgical site infection., Infection and immunity, 81, (12), 2013, p4478-4489
Yang, M., Flavin, K., Kopf, I., Radics, G., Hearnden, C.H.A., McManus, G.J., Moran, B., Villalta-Cerdas, A., Echegoyen, L.A., Giordani, S., Lavelle, E.C., Functionalization of carbon nanoparticles modulates inflammatory cell recruitment and NLRP3 inflammasome activation, Small, 9, (24), 2013, p4194-4206
Hearnden, C., Lavelle, E.C., Adjuvant Strategies for Vaccines: The Use of Adjuvants within the Cancer Vaccine Setting, Cancer Immunotherapy: Immune Suppression and Tumor Growth: Second Edition, 2013, p333-349
Tynan, G.A., McNaughton, A., Jarnicki, A., Tsuji, T., Lavelle, E.C., Polymyxin B inadequately quenches the effects of contaminating lipopolysaccharide on murine dendritic cells, PLoS ONE, 7, (5), 2012
Cunningham CC, Mills E, Mielke LA, O'Farrell LK, Lavelle E, Mori A, McCarthy GM, Mills KH, Dunne A, Osteoarthritis-associated basic calcium phosphate crystals induce pro-inflammatory cytokines and damage-associated molecules via activation of Syk and PI3 kinase., Clinical immunology (Orlando, Fla.), 144, (3), 2012, p228-236
Doyle SL, Campbell M, Ozaki E, Salomon RG, Mori A, Kenna PF, Farrar GJ, Kiang AS, Humphries MM, Lavelle EC, O'Neill LA, Hollyfield JG, Humphries P, NLRP3 has a protective role in age-related macular degeneration through the induction of IL-18 by drusen components., Nature medicine, 18, (5), 2012, p791-798
McNeela, E.A., Lavelle, E.C., Recent advances in microparticle and nanoparticle delivery vehicles for mucosal vaccination, Current Topics in Microbiology and Immunology, 354, (1), 2012, p75-99
Campbell*, M, Doyle*, SL, Ozaki, E, Salomon, RG, Mori, A, Kenna, PF, Kiang, AS, Humphries, MM, Lavelle, EC, O'Neill, LAJ, Hollyfield, JG, and Humphries, P, NLRP3 plays a protective role during the development of age related macular degeneration through the induction of IL-18 by drusen components., Nature Medicine, 18, (5), 2012, p791 - 798
Peral de Castro C, Jones SA, Ní Cheallaigh C, Hearnden CA, Williams L, Winter J, Lavelle EC, Mills KH, Harris J, Autophagy Regulates IL-23 Secretion and Innate T Cell Responses through Effects on IL-1 Secretion., Journal of immunology (Baltimore, Md. : 1950), 189, (8), 2012, p4144-4153
Immunostimulatory properties of biodegradable microparticles in, editor(s)John H. Morrow, Clint Schmidt, Nadeem Sheikh, Huw Davies , Vaccinology: Principles and Practice., Wiley-Blackwell, 2012, [Sharp, F.A. and Lavelle, E.C ]
Mori, A., Oleszycka, E., Sharp, F.A., Coleman, M., Ozasa, Y., Singh, M., O'Hagan, D.T., Tajber, L., Corrigan, O.I., McNeela, E.A., Lavelle, E.C., The vaccine adjuvant alum inhibits IL-12 by promoting PI3 kinase signaling while chitosan does not inhibit IL-12 and enhances Th1 and Th17 responses, European Journal of Immunology, 42, (10), 2012, p2709-2719
McNeela, E.A. and Lavelle, E.C. , Recent advances in microparticles and nanoparticles for mucosal vaccination , Current Topics in Microbiology and Immunology, 354, 2012, p75-99
Schijns,V.E.J.C and Lavelle, E.C, Trends in vaccine adjuvants. , Expert Reviews in Vaccines., 10, (4), 2011, p539 - 550
Ruane D.T and Lavelle E.C. , The role of CD103+ dendritic cells in the intestinal mucosal immune system. , Frontiers in Immunology , 2, 2011, p25
Rationales for including adjuvants in vaccines in, editor(s)Duc Hong Le , Novel Immunologic Adjuvants, Future Medicine Ltd, 2011, pp6 - 14, [Schijns, V.E.J.C. and Lavelle, E.C]
Lavelle, E.C., McNaughton, A. and McNeela, E.A., NLRP3 in protective immunity and vaccination against respiratory infection, Expert Review of Vaccines, 10, (3), 2011, p255 - 257
Future Trends of Novel Vaccine Adjuvants in, editor(s)Duc Hong Le, E , Immunologic Adjuvants, Future Science Group, 2011, pp104 - 116, [Schijns, V.E.J.C. and Lavelle, E.C]
Brereton, C.F., Sutton, C.E., Ross, P.J., Iwakura, Y., Pizza, M., Rappuoli, R., Lavelle, E.C., Mills, K.H.G., Escherichia coli heat-labile enterotoxin promotes protective Th17 responses against infection by driving innate IL-1 and IL-23 production, Journal of Immunology, 186, (10), 2011, p5896-5906
Afonina, I.S., Tynan, G.A., Logue, S. E., Cullen, S.P., Bots, M., Lüthi, A.U., Reeves, E.P., McElvaney, N.G., Medema, J.P., Lavelle, E.C. and Martin, S.J., Granzyme B-dependent proteolysis acts as a switch to enhance the pro-inflammatory activity of IL-1, Molecular Cell, 44, (2), 2011, p465 - 478
Harris, J..Hartman, M., Roche, C., Zeng, S.G., O'Shea, A., Sharp, F.A., Lambe, E.M., Creagh, E.M., Golenbock, D.T., Tschopp, J., Kornfeld, H., Fitzgerald, K.A. and Lavelle, E.C , Autophagy controls IL-1ß secretion by targeting pro-IL-1ß for degradation, The Journal of Biological Chemistry, 286, 2011, p9587 - 9597
Ní Cheallaigh C, Keane J, Lavelle EC, Hope JC, Harris J., Autophagy in the immune response to tuberculosis: clinical perspectives., Clinical and Experimental Immunology, 164, (3), 2011, p291 - 300
Discovery of vaccine adjuvants in, editor(s)Editor Shane C. Gad. , Pharmaceutical Sciences Encyclopedia: Drug Discovery, Development, and Manufacturing., John Wiley & Sons , 2011, pp1 - 14, [Sharp, F. and Lavelle, E.C.]
Masters, S.L., Dunne, A., Subramanian, S.L., Hull, R.L., Tannahill, G.M., Sharp, F.A., Becker, C., Lavelle,E.C. and O'Neill, L.A.J., Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1β 2 in type 2 diabetes , Nature Immunology, 11, (10), 2010, p897-904
Harris, J., Sharp, F.A. and Lavelle, E.C, The role of inflammasomes in the immunostimulatory effects of particulate vaccine adjuvants , European Journal of Immunology , 40, (3), 2010, p634-638
Sutton CE, Lalor SJ, Sweeney CM, Brereton CF, Lavelle EC, Mills KH., Response: Characteristics of IL-17-Producing gammadelta T Cells., Immunity, 32, (1), 2010, p3 - 4
McNeela EA, Burke A, Neill DR, Baxter C, Fernandes VE, Ferreira D, Smeaton S, El-Rachkidy R, McLoughlin RM, Mori A, Moran B, Fitzgerald KA, Tschopp J, Pétrilli V, Andrew PW, Kadioglu A, Lavelle EC, Pneumolysin activates the NLRP3 inflammasome and promotes proinflammatory cytokines independently of TLR4., PLoS pathogens, 6, (11), 2010, pe1001191
Lavelle EC, Murphy C, O'Neill LA, Creagh EM, The role of TLRs, NLRs and RLRs in mucosal innate immunity and homeostasis , Mucosal Immunology, 3, (1), 2010, p17 - 28
Harris, J., Hope, J. and Lavelle, E.C. , Autophagy and the immune response to TB, Transboundary and Emerging Diseases , 56, (6-7), 2009, p248-254
Sharp, F., Ruane, D., Claas, B., Creagh, E., Harris, J., Malyala, P., Singh, M., O'Hagan, D.T., Pétrilli, V., Tschopp, J., O'Neill, L.A.J. and *Lavelle, E.C, Uptake of particulate vaccine adjuvants by dendritic cells activates the NALP3 inflammasome., Proceedings of the National Academy of Sciences of the U.S.A, 106, (3), 2009, p870-875
Oral delivery of vaccines in, editor(s)J Fix. and V H.L. Lee , Oral Peptide and Protein Drug Delivery, New York , Marcel Dekker, 2009, [Lavelle, E.C. and O'Hagan, D.T.]
Lavelle, E.C., Thanavala, J. and Ogra,P. , Mucosal immunity on the banks of the Duoro, Human Vaccines, 5, (5), 2009, p1 - 3
Thanavala,Y., Lavelle, EC. and Ogra,P. , All things mucosal, Expert Reviews in Vaccines , 8, (2), 2009, p139 - 142
Alexander U. Lüthi, Sean P. Cullen, Edel A. McNeela, Patrick J. Duriez, Inna S. Afonina, Clare Sheridan, Gabriela Brumatti, Rebecca C. Taylor, Kristof Kersse, Peter Vandenabeele, Ed C. Lavelle, and Seamus J. Martin, Suppression of Interleukin-33 Bioactivity through Proteolysis by Apoptotic Caspases, Immunity, 31, (1), 2009, p84-98
Sutton, C.E., Lalor, S.J., Sweeney, C.M., Brereton, C.F., Lavelle, E.C. and Mills, K.H.G , Interleukin-1 and IL-23 induce innate IL-17 production from gammadelta T cells, amplifying Th17 responses and autoimmunity., Immunity, 31, (2), 2009, p331-341
Brereton CF, Sutton CE, Lalor SJ, Lavelle EC, Mills KH., Inhibition of ERK MAPK suppresses IL-23- and IL-1-driven IL-17 production and attenuates autoimmune disease., Journal of Immunology, 183, (3), 2009, p1715-2173
Jarnicki, AJ, Conroy, H. Brereton, C, Donnelly, G., Toomey, D., Walsh, K.,, Sweeney, C., Leavy, O., Fletcher, J., Lavelle, E., Dunne, P. and Mills, K.H.G., Attenuating regulatory T cell induction by TLR agonists through inhibition of p38 MAPK signaling in dendritic cells enhances their efficacy as vaccine adjuvants and cancer immunotherapeutics, Journal of Immunology, 180, (6), 2008, p3797 - 3806
Lavelle EC, Lectins and microparticles for enhanced oral vaccination, Methods, 38, (2), 2006, p84 - 89
Lavelle E.C., Evaluation of the binding, uptake and immune responses elicited to orally administered lectins and microparticles, Methods , 38, (2), 2006, p84-89
Mills, K.H.G., Higgins, S.H and Lavelle, E.C. , Tracheal Cytotoxin/ "Methods and compositions for modulating and immune response, 2006
Lavelle, E.C. and O'Hagan, D.T, Delivery systems and adjuvants for oral vaccines, Expert Opinion on Drug Delivery , 3, (6), 2006, p747 - 762
Higgins, S., Jarnicki, A, Lavelle, E.C. and Mills, K.H.G, TLR4 mediates vaccine-induced protective cellular immunity to Bordetella pertussis: role of IL-17-producing T cells, The Journal of Immunology, 177, 2006, p7980 - 7989
Sutton, C., Brereton, C., Keogh, B., Mills, K.H.G. Lavelle, E.C., A crucial role for IL-1 in the induction of IL-17 producing T cells that mediate autoimmune encephalomyelitis, The Journal of Experimental Medicine, 203, (7), 2006, p1685 - 1691
Lavelle, E.C., Grant, G., Pfuller,U. and O'Hagan, D.T, Type II ribosome-inactivating proteins from mistletoe are effective adjuvants when administered by mucosal and transcutaneous routes, Vaccine , Supplement 2, (S2), 2006
Lavelle, E.C, Generation of improved mucosal vaccines by induction of innate immunity., Cellular And Molecular Life Sciences, 62, (23), 2005, p2750-2770
Modified bacterial toxins in, editor(s)Charles J Hackett & Donald A Harn Jr, , Vaccine Adjuvants: Immunological and Clinical Principles., Publisher Humana, 2005, pp296 , [Lavelle EC., Leavy O. Mills KHG. ]
Boyd, A.P., Ross, P.J., Conroy, H., Mahon, N Lavelle, E.C.and Mills, K.H.G., Bordetella pertussis adenylate cyclase toxin modulates innate and adaptive immune responses: distinct roles for acylation and enzymatic activity in immunomodulation and cell death, Journal of Immunology, 175, 2005, p730 - 738
Armstrong ME, Lavelle EC, Loscher CE, Lynch MA, Mills KHG, Proinflammatory Responses in the Murine Brain after Intranasal Delivery of Cholera Toxin: Implications for the Use of AB Toxins as Adjuvants in Intranasal Vaccines, Journal of Infectious Diseases, 192, (9), 2005, p1628 - 1633
Lavelle EC., Grant G., Pfuller U. and O'Hagan D.T, Immunological implications of the use of plant lectins for drug and vaccine targeting to the gastrointestinal tract, The Journal of Drug Targeting , 12, (2), 2004, p89 - 95
Lavelle, E.C., McGuirk, P. and Mills, K.H.G. , Molecules of Infectious Agents as Immunomodulatory Drugs, Current Medicinal Chemistry , 4, (5), 2004, p499 - 508
Ross, P.J., Lavelle, E.C., Mills, K.H.G. and A.P. Boyd., Adenylate cyclase toxin from Bordetella pertussis synergises with lipopolysaccharide to promote innate IL-10 production and enhance the induction of Th2 and regulatory T cells, Infection and Immunity, 72, (3), 2004, p1568 - 1579
Lavelle, E., McGuirk and Mills, K.H.G., Molecules of infectious agents as immunomodulatory drugs, Current Topics in Med. Chem., 4, (5), 2004, p499 - 508
Bowe, F., Lavelle, E.C., McNeela, E. A., Hale, C., Clare, S., Arico, B., Giuliani, M.M., Rae, A., Huett, A., Rappuoli, R., Dougan, G. and Mills, K. H.G., Mucosal vaccination against serogroup B meningococcus:Induction of bactericidal antibodies and cellular immunity following intranasal immunization with NadA of Neisseria meningitidis and mutants of Escherichia coli heat-labile enterotoxin, Infection and Immunity, 72, (7), 2004, p4052 - 4060
Lavelle EC, Jarnicki A, McNeela E, Armstrong ME, Higgins SC, Leavy O, Mills KHG, Effects of cholera toxin on innate and adaptive immunity and its application as an immunomodulatory agent, Journal of Leukocyte Biology, 75, (5), 2004, p756 - 763
Lavelle, E., McNeela, E., Armstrong, M., Leavy, O., Higgins, S.C. and Mills K.H.G., Cholera toxin promotes the induction of regulatory T cells by modulation dendritic cell activation, The Journal of Immunology, 171, 2003, p2384 - 2392
Higgins, S., Lavelle, E., McCann, C., Keogh, B., McNeela, E, Byrne, P., O'Gorman, B., Jarnicki, A., McGuirk, P. and Mills, K.H.G., Toll-like receptor 4-mediated innate IL-10 activates antigen-specific regulatory T cells and confers resistance to Bordetella pertussis by inhibiting inflammatory pathology, Journal of Immunology, 171, (6), 2003, p3119 - 3127
Mills, K.H.G., Boyd, A.P., Ross, P.J. and Lavelle, EC., , CyaA in the prophylaxis/treatment of inflammatory and immune-mediated disorders., 2003
O'Hagan, D.T and Lavelle, E. , Novel adjuvants and delivery systems for HIV vaccines, AIDS, 16, 2002, pS115 - S124
Lavelle EC, Grant G, Pusztai A, Pfüller U, Leavy O, McNeela E, Mills KH, O'Hagan DT., Mistletoe lectins enhance immune responses to intranasally co-administered herpes simplex virus glycoprotein D2., Journal of Immunology, 107, (2), 2002, p268 - 274
Lavelle, E.C., Chiron Corporation, Plant lectins as mucosal adjuvants. , 2001, WO0134193
Lavelle, E.C, Targeted delivery of drugs to the gastrointestinal tract, CRC Critical Reviews in Therapeutic Drug Carrier Systems, 18, (4), 2001, p341 - 386
Lavelle, E.C., Grant, G., Pusztai,A., Pfüller,U and O'Hagan, D.T. , The identification of plant lectins with mucosal adjuvant activity, Immunology, 102, (1), 2001, p77 - 86
Lavelle E.C, Patent update on drug delivery: January-June, Expert Opinion on Therapeutic Patents , 10, (9), 2000, p1335 - 1343
Lavelle E.C, Targeted mucosal delivery of drugs and vaccines, Expert Opinion on Therapeutic Patents , 10, (2), 2000, p179 - 190
Lavelle, E.C., Grant, G., Pusztai,A., Pfüller,U and O'Hagan, D.T. , Mucosal immunogenicity of plant lectins in mice., Immunology, 99, (1), 2000, p30 - 37
Gill, I.J., Lin,W., Jenkins,P., Watts,P., Jiminez,M., Illum,L., Davis,S.S., Wood,J.M., Major,D., Minor,P.D., Li,X., Lavelle,E.C. and Coombes,A.G.A. , Potential of polymeric lamellar substrate particles (PLSP) as adjuvants for vaccines, Vaccine, 18, (3-4), 2000, p238 - 250
Delgado, A., Lavelle, E.C., Hartshorne,M. and Davis, S.S. , PLG microparticles stabilised using enteric coating polymers as oral vaccine delivery systems. , Vaccine, 12, (22), 1999, p2927 - 2938
Lavelle, E.C., Yeh, M.K., Coombes, A.G.A. and Davis, S.S., The stability and immunogenicity of a protein antigen encapsulated in biodegradable microparticles based on blends of lactide polymers and polyethylene glycol. , Vaccine, 17, (6), 1999, p512 - 529
Lectins in oral vaccination. in, editor(s)Eds, S. Bardocz., G. Hajós and A. Pusztai , COST 98-Effects of antinutrients on the nutritional value of legume diets., European Commission., 1999, pp148-159. , [Lavelle,E.C ]
Coombes, A.G.A., Lavelle,E.C. and Davis, S.S. , Biodegradable lamellar particles of poly (lactide) induce sustained immune responses to a single dose of adsorbed protein. , Vaccine, 17, (19), 1999, p2410 - 2422
Coombes, A.G.A., Yeh, M-K., Lavelle, E.C. and Davis, S.S. , The control of protein release from poly (DL lactide-co-glycolide) microparticles by variation of the external aqueous phase surfactant in the water-in oil-in water method. , The Journal of Controlled Release, 52, (3), 1998, p311 - 320
Takahata, H., Lavelle, E.C., Coombes, A.G.A., Rafati, H. and Davis, S.S. , An investigation into the effects of exposure to digestive enzymes and polymer degradation on the integrity of microparticle-associated antigen. , The Journal of Controlled Release , 50, (1-3), 1998, p237 - 248
Lavelle, E.C., Jenkins, P.G. and Harris, J.E. , Oral immunisation of rainbow trout with antigen microencapsulated in PLG microparticles. , Vaccine, 15, (10), 1997, p1070 - 1078
Lavelle, E. C. and Harris, J. E. , The proteolysis of an orally administered protein antigen in the digestive tract of rainbow trout, Oncorhynchus mykiss (Walbaum,1792). , Comparative Biochemistry and Physiology, 117, (2), 1997, p263 - 275
Coombes, A.G.A., Lavelle, E.C., Jenkins, P. G. and Davis, S. S. , Single dose, polymeric, microparticle-based vaccines: the influence of formulation conditions on the magnitude and duration of the immune response to a protein antigen, Vaccine, 14, (14), 1996, p1429 - 1438
Rafati, H., Lavelle, E.C., Coombes, A.G.A., Stolnik, S., Holland, J. and Davis, S.S., The immune response to a model antigen associated with PLG microparticles prepared using different surfactants, Vaccine, 15, (17-18), 1996, p1888 - 1897
Thomas, N. W., Jenkins, P.G., Howard, K.A., Smith, M.W., Lavelle, E.C., Holland,J. and Davis, S.S. , Particle uptake and translocation across epithelial membranes, The Journal of Anatomy, 189, (3), 1996, p487 - 490
Coombes, A.G.A., Lavelle, E.C., Jenkins, P. G., Holland, J. and Davis, S. S. , Biodegradable microparticles as parenteral vaccine delivery systems. , Developments in Biological Standardization , 87, 1996, p231-
Lavelle, E.C., Sharif, S., Thomas, N. W., Holland, J. and Davis, S. S. , The importance of gastrointestinal uptake of particles in the design of oral delivery systems. , Advanced Drug Delivery Reviews, 18, (1), 1995, p5 - 22
Coombes, A.G.A., Lavelle, E.C., Jenkins, P.G. and Davis, S.S., Pulsed and sustained immune responses following a single dose of a model antigen associated with resorbable microparticles, Proceedings of International Symposium on the Controlled Release of Bioactive Materials. , 226-230, 1995, p560-561
Jenkins, P.G., Barton, R.N., Harris, J.E., Lavelle, E.C. and Wrathmell, A.B. , Enhanced delivery systems for enteric antigen uptake in teleosts, Vaccine, 10, 1992, p281-282
Research Expertise
Description
I am an internationally recognised leader in the field of vaccine adjuvants with a record of publishing high impact papers, attracting competitive research funding, generating and protecting intellectual property, engaging industrial partners and the public, organising conferences and adopting advisory roles. Adjuvants are essential components of vaccines that can profoundly enhance protective immune responses and specifically can affect the magnitude and type of vaccine -induced innate and adaptive immunity. My research is principally focused on how vaccine adjuvants enhance protective immune responses against infection and cancer. My group has made key discoveries that enhance our understanding of how the physicochemical properties of adjuvants influence the induction of innate and adaptive immunity. We have provided major new insights into how adjuvants engage innate cellular sensing pathways, particularly DNA sensing pathways and inflammasomes, pursuing the specific roles of interferons and cytokines of the IL-1 family in adjuvanticity. We have developed novel particulate vaccine adjuvants (IP filed, new start up in cancer vaccines launched - AilseVax). We have worked on developing an effective oral delivery system that has significant potential for vaccines against ETEC, cholera and Helicobacter pylori. The expertise we have developed in assessing particulate adjuvant regulation of immune responses also has relevance in the field of biomaterial interaction with the immune system. As a result, I have a substantial research programme in this area as part of the AMBER centre. Being a CRANN PI and an AMBER funded investigator has led to close connections with colleagues in Bioengineering, Chemistry and Physics and this cross-disciplinary dimension places my research in a unique position within Ireland. This allows me to pursue how particulate materials can regulate immune responses and how fundamental understanding of the underlying processes can help us to rationally design novel vaccine adjuvant systems but also enhanced biomaterials. My work at Trinity has been transformational over the past 17 years in establishing that nonmicrobial particulate adjuvants can be designed to activate specific innate sensing and signalling pathways and that this can be harnessed to induce and direct adaptive immune responses. This has led to publications in the leading journals in the field, many since my last promotion in 2015. The impact of my work can be seen in invitations to speak at the leading meetings in the field (111 invited conference talks and seminars since 2004), to serve on scientific advisory boards for conferences (15), to serve as chair on the advisory board of a vaccine centre in the U.K., to act as a consultant for leading (Merck, GSK, HIPRA) vaccine companies, to write reviews, commentaries and editorials and to serve as a panel member for prestigious grant agencies (e.g. Gates Foundation, German Centres of Excellence Programme). Being recognised as an authority in vaccine adjuvant research together with the global prominence of this field makes it likely that my influence will grow, generating many new research opportunities over the coming years.Projects
- Title
- Tailored design of nanoparticulate adjuvants to enhance vaccine induced cellular immunity
- Funding Agency
- Science Foundation Ireland
- Date From
- 1-10-2020
- Date To
- 30-9-2025
- Title
- Adjuvants targeting the NLRP3 inflammasome and STING for improved cancer immunotherapy.
- Funding Agency
- Irish Research council
- Date From
- 1-10-2019
- Date To
- 30-9-2-23
- Title
- Potential of oral cyclosporine to treat extra-intestinal diseases
- Funding Agency
- Sublimity Therapeutics
- Date From
- 1-5-2019
- Date To
- 30-9-2020
- Title
- Sugar coating immunity for enhancement of biomaterials.
- Summary
- 18/TIDA/6087.
- Funding Agency
- Science Foundation Ireland
- Date From
- 1-1-2019
- Date To
- 31-10-2020
- Title
- Irish Society for Immunology meeting 2018.
- Summary
- Proposal ID: 18/CW/5605.
- Funding Agency
- Science Foundation Ireland (SFI)
- Date From
- 1-6-2018
- Date To
- 31-12-2018
- Title
- European Congress of Immunology
- Summary
- The Business Tourism Unit of the National Tourism Development Authority (Fáilte Ireland) has approved an offer of grant assistance in respect of the above conference.
- Funding Agency
- Failte Ireland
- Date From
- 14-3-2018
- Date To
- 31-12-2024
- Title
- Investigating the role of Mal/TIRAP and the Mal- S180L SNP as determinants of susceptibility to pneumococcal disease and antipneumoco ccal vaccine efficacy
- Funding Agency
- European Society for Clinical Microbiolo gy and Infectious Diseases (ESCMID)
- Date From
- 1-5-2018
- Date To
- 31-10-2019
- Title
- SFI Research Centre, Advanced Materials and Bioengineering Research (AMBER) centre
- Summary
- Co-applicant for funding: Grant number SFI/12/RC/2278. Funded investigator. Projected budget to Ed Lavelle 904,000k
- Funding Agency
- SFI
- Date From
- 2013
- Date To
- 2019
- Title
- Novel combination strategies for enhancing efficacy of immune checkpoint inhibitors in the treatment of cancer
- Funding Agency
- Trinity St. James's Cancer Institute
- Date From
- 2018
- Date To
- 2019
- Title
- Improving vaccine responses in the paediatric population by harnessing cytosolic nucleic acid sensing responses to promote Th1 and Th17 cell polarisation
- Summary
- Co-PI with Dr Sarah Doyle.
- Funding Agency
- National Childrens Research Centre
- Date From
- 1-1-2017
- Date To
- 31-12-2019
- Title
- Modulation of innate and adaptive immunity by particulate adjuvants for improved parenteral and mucosal vaccination.
- Summary
- 12/1A/1421.
- Funding Agency
- SFI
- Date From
- 2013
- Date To
- 2019
- Title
- Targeted oral delivery of cyclosporine to inhibit pathological intestinal IL-17 responses.
- Summary
- Project ID: EPSPG/2017/302.
- Funding Agency
- Irish Research Council
- Date From
- 1-1-2018
- Date To
- 1-1-2022
- Title
- RAdiosensitising Yb-1 Nano-antiBOdy (RAYNBO): a proof of concept study
- Funding Agency
- Trinity St. James's Cancer Institute
- Date From
- 2018
- Date To
- 2019
- Title
- Irish Society for Immunology meeting 2017
- Funding Agency
- Science Foundation Ireland (SFI)
- Date From
- 2017
- Date To
- 2017
- Title
- Investigating the Mal-IFN-γ axis as a determinant of morbidity and mortality in pneumococcal disease.
- Summary
- IRC award to Dr Natalia Munoz-Wolf.
- Funding Agency
- Irish Research Council
- Date From
- 1-10-2017
- Date To
- 31-9-2019
- Title
- Mechanism of action of chitin derived polymers
- Funding Agency
- Trinity College Dublin
- Date From
- 1-9-2017
- Date To
- 1-9-2021
- Title
- Mode of action of oral vaccine adjuvants
- Summary
- FNS P300PB_164740
- Funding Agency
- Swiss National Science Foundation (SNSF)
- Date From
- 1-2-2016
- Date To
- 31-1-2019
- Title
- Immunomodulatory properties of rhamnose
- Summary
- Trinity College Dublin College Award to Mimmi Lundahl. 39,000 (2015-2018)
- Funding Agency
- Trinity College Dublin
- Date From
- 1-10-2015
- Date To
- 1-10-2019
- Title
- Irish Society for Immunology meeting 2015.
- Funding Agency
- Science Foundation Ireland (SFI)
- Date From
- 1-6-2015
- Date To
- 31-12-2015
- Title
- Innate immune training: a memorable encounter with adjuvants
- Summary
- Project ID GOIPG/2015/4023. Aoife Gorman.
- Funding Agency
- Irish Research Council
- Date From
- 1-10-2015
- Date To
- 31-9-2019
- Title
- Irish Society for Immunology Workshop on the Microbiota and Clinical Immunology.
- Summary
- .14/CW/B016.
- Funding Agency
- Science Foundation Ireland (SFI)
- Date From
- 2014
- Date To
- 2014
- Title
- Targeting innate lymphoid cells in oral vaccination
- Funding Agency
- Saudi Arabian Government/Saudi Arabian Cultural Bureau.
- Date From
- 1-3-2015
- Date To
- 28-2-2019
- Title
- Advanced Immunization Technologies ADITEC
- Summary
- Co applicant: Affiliated member. Budget to Lavelle lab 47k.
- Funding Agency
- European Union
- Date From
- 2012
- Date To
- 2017
- Title
- HELICOVAXOR (2013), Development of novel mucosal vaccines against Helicobacter pylori infection.
- Summary
- Amount awarded is 1.3. Budget allocated to Dr Ed Lavelle 250,900. My role is as an RTD performer working on mucosal vaccination and determination of antigen specific cellular and humoral immunity.
- Date From
- 2013
- Date To
- 2015
- Title
- Targeted delivery of particulate vaccine adjuvants. (2011).
- Summary
- EPSPG/2012/404. Principal Investigator.
- Funding Agency
- Irish Research Council for Science, Engineering and Technology
- Date From
- 2010
- Date To
- 2013
- Title
- Targeted mucosal vaccines for HIV-Postgraduate award. 2010
- Summary
- Principal Investigator.
- Funding Agency
- Irish Research Council for Science, Engineering and Technology
- Date From
- 2010
- Date To
- 2013
- Title
- Development of novel immunostimulators to boost the immune system in cattle.
- Summary
- Adacemic Principal Investigator
- Funding Agency
- TEAGASC
- Date From
- 2012
- Title
- Immunomodulatory properties of nanoparticulates.
- Summary
- 12 month project focusing on carbon based nanoparticles. Time commitment 4%.
- Date From
- 2011
- Title
- European Mucosal Immunology Group meeting 2012
- Summary
- 12/CW/B2256. (EMIG2012).
- Funding Agency
- SFI
- Date From
- 2012
- Title
- Development of novel oral vaccines using LEDDS technology.
- Summary
- (2010).IRCSET-Sigmoid 2010-01. 2010-2013. Time commitment 4%.
- Funding Agency
- Irish Research Council for Science, Engineering and Technology
- Date From
- 2010
- Date To
- 2013
- Title
- Optimisation of liquid emulsion drug delivery system (LEDDS based oral vaccines to promote protective immunity against mucosal pathogens.
- Summary
- (2010). Proposal ID, IP20090046. Principal investigator.
- Funding Agency
- Enterprise Ireland
- Date From
- 2010
- Date To
- 2012
- Title
- Development of novel Liquid/Emulsion Drug Delivery System (LEDDS ) formulations for oral vaccination IP 2007 0451
- Summary
- Development of novel delivery systems for oral vaccination
- Funding Agency
- Enterprise Ireland
- Date From
- 2007
- Date To
- 2009
- Title
- Development of potent mucosal vaccines by combining an effective targeting agent with immunostimulatory particulate adjuvants.
- Summary
- Proposal ID, IP20090022. Principal investigator.
- Funding Agency
- Enterprise Ireland
- Date From
- 2010
- Date To
- 2012
- Title
- Can the ability of chitosan to promote innate immunity be harnessed to develop safe and potent adjuvants? (2008)
- Summary
- Proposal ID. 08/RFP/BMT1363. Principal Investigator.
- Funding Agency
- Science Foundation Ireland
- Date From
- 2008
- Date To
- 2011
- Title
- 'The Identification of novel immunomodulatory factors from Neisseria meningitidis serogroup B'
- Summary
- : Use of high throughput protein expression and dendritic cell screening technologies to identify novel adjuvants. Principal Investigator.
- Funding Agency
- Meningitis Research Foundation/Health Research Board
- Date From
- 2007
- Date To
- 2010
- Title
- SFI Strategic Research Cluster Grant. (2008).
- Summary
- Co-applicant for funding: Cluster. 7.5m. Co-applicant, PI Prof Kingston Mills. Budget allocated to Dr Ed Lavelle 794,498.
- Funding Agency
- SFI Strategic Research Cluster Grant.
- Date From
- 2008
- Date To
- 2012
- Title
- Mucosal vaccines for TB, HIV and malaria
- Funding Agency
- EU
- Date From
- 2004
- Date To
- 2009
- Title
- Development of novel Liquid/Emulsion Drug Delivery System (LEDDS ) formulations for oral vaccination (2007)
- Summary
- IP 2007 0451. Principal Investigator.
- Funding Agency
- Enterprise Ireland
- Date From
- 2007
- Date To
- 2009
- Title
- HRB PhD Scholars programme in Immunology.
- Summary
- Coapplicant for funding: Awarded to Trinity College Dublin in partnership with the Institute of Immunology (NUI Maynooth) and the Division of infection and Immunity (Queens University Belfast). Partner. Budget allocated to Dr Ed Lavelle (303,360).
- Funding Agency
- HRB
- Date From
- 2007
- Date To
- 2011
- Title
- Does Epac mediate a cyclic AMP-inducible pathway in dendritic cells that promotes pro-inflammatory T cell responses?
- Summary
- proposal ID: 07/RFP/BICF537. Principal Investigator.
- Funding Agency
- Science Foundation Ireland
- Date From
- 2007
- Date To
- 2010
- Title
- Determination of the potential of novel LEDDS formulations as oral vaccine delivery systems
- Summary
- IP 2006 0422 Principal Investigator
- Funding Agency
- Enterprise Ireland
- Date From
- March 07
- Date To
- May 07
- Title
- Mechanism of action of alum as a vaccine adjuvant.
- Summary
- Summary: Investigation of the mechanisms by which alum activates and polarizes T cell responses, focusing on its effects on dendritic cells. Principal Investigator.
- Funding Agency
- Irish Research Council for Science, Engineering and Technology
- Date From
- 2006
- Date To
- 2009
- Title
- Development of patented targeting technologies to produce oral vaccines.
- Summary
- IP 2006 0372. Summary: Investigation of novel cell targeting technologies to enhance mucosal vaccines. Principal Investigator.
- Funding Agency
- Enterprise Ireland
- Date From
- 2006
- Date To
- 2007
- Title
- A determination of the efficacy of LEDDS as an oral vaccine delivery system.
- Summary
- Summary: Investigation of novel delivery systems for oral vaccines. Principal Investigator.
- Funding Agency
- Sigmoid Biotechnologies Limited (2006).
- Date From
- 2006
- Date To
- 2007
- Title
- 'Mucosal vaccines for poverty related diseases'
- Summary
- Co-applicant for funding: Project acronym: MUVAPRED. Title of grant: . Amount awarded was 350,000. 2003-2007. Summary: Development of mucosal vaccines for malaria, TB and HIV using novel mucosal adjuvants and delivery systems. Partner.
- Funding Agency
- EU
- Date From
- 2003
- Date To
- 2007
Recognition
Representations
Chair of the Steering committee for the Centre for Global Vaccine Research, University of Liverpool, U.K. (2017-2020).
Main organiser of 9 Immunology meetings including the Irish Society for Immunology meetings (2013-2020; average attendance 160-200 participants) and the European Mucosal Immunology Group (EMIG) 2012 meeting (300 participants), held in Dublin.
Member of the advisory board for the EU funded ITN, PHA-ST-TRAIN-VAC between the University of Strathclyde and GSK Vaccines (2017-2019).
National representative and member of the core group of the COST Action ENOVA (European Network of Vaccine adjuvants) 2018-2022.
Member of the Scientific Advisory Panel for 13 international conferences since 2006.
Won the bid to host the 2024 European Congress of Immunology in Dublin in 2024. I will lead the committee in planning for this meeting for the coming 5 years.
Member of the Editorial Board of Biochemical Pharmacology and Frontiers in Immunology
Awards and Honours
Elected a Member of the Royal Irish Academy (MRIA)
Fellow of Trinity College Dublin (FTCD)
Elected President of the Irish Society for Immunology
Elected President of the European Congress of Immunology 2024 (ECI2024)
Made an ambassador of the Dublin Convention Centre
Memberships
Irish Society for Immunology (President 2008-2020)
Committee member of the Vaccine committee for the International Union of Immunological Societies (IUIS).
European Federation of Immunology Societies
International Society of Vaccines
Society for Mucosal Immunology
The American Association of Immunologists
European Adjuvant Advisory Group